I-Mab’s (NBP) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of I-Mab (NASDAQ:NBP) in a report released on Thursday,Benzinga reports. The firm currently has a $9.00 target price on the stock.

Separately, Weiss Ratings raised I-Mab from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 1st. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $9.00.

I-Mab Trading Up 4.7%

Shares of I-Mab stock opened at $2.00 on Thursday. The company has a market cap of $231.30 million, a PE ratio of -5.56 and a beta of 1.47. The business has a fifty day moving average of $1.78. I-Mab has a one year low of $1.46 and a one year high of $6.79.

I-Mab (NASDAQ:NBP) last released its quarterly earnings results on Thursday, August 20th. The company reported ($0.16) earnings per share (EPS) for the quarter. As a group, equities research analysts anticipate that I-Mab will post -0.3 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in I-Mab stock. Brooklyn Investment Group bought a new position in I-Mab (NASDAQ:NBP) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 12,715 shares of the company’s stock, valued at approximately $51,000. 38.38% of the stock is currently owned by institutional investors.

I-Mab Company Profile

I-Mab is a clinical-stage biotechnology company focused on the discovery, development and commercialization of biologic therapies for oncology and immunology indications. The company concentrates on advancing antibody-based therapeutics and other protein biologics intended to modulate the immune system to treat cancer and autoimmune or inflammatory diseases. Its development activities span preclinical research through late-stage clinical trials, with an emphasis on creating targeted, differentiated molecules designed to address unmet medical needs.

Headquartered in China with global development activities, I-Mab operates research and development facilities and engages with clinical investigators and regulatory authorities across multiple geographies to support global clinical programs.